Secretariat Time Programme
Daily
12:00 - 13:30

sfe

Sivolapenko Gregory
Tel. : (+302610) 962323  /  962324
Fax : (+302610)
E-mail: This e-mail address is being protected from spambots. You need JavaScript enabled to view it

 
Education
1990: Ph.D. in Medicine (Clinical Oncology & Immunology), University of London, UK
1984: B.Sc. in Pharmacy, University of Athens, Greece
Current position
Associate Professor of Pharmacokinetics, Director Laboratory of Pharmacokinetics, Department of Pharmacy, University of Patras, Greece
Research Activities
Preclinical and clinical studies of bioavailability and pharmacokinetics of new chemical entities.
Pharmacokinetic and pharmacodynamics interactions. Toxicokinetics.
Pharmacokinetic and Pharmacogenomic interactions.
Drug clinical development, design & conduct of Phase I-IV clinical trials.
Publications
Publications in international peer reviewed journals: 49
Invited reviews in international books: 6
Articles in international meeting proceedings: 3
Articles in Greek meeting proceedings: 13
Greek publications: 3
Organisation of scientific congresses & seminars
International: 29
National: 28
Current teaching activities
Undergraduate: Biopharmacy and Pharmacokinetics, Clinical Pharmacy, Pharmaceutical Immunology, , Bioethics and Pharmaceutical Law (Department of Pharmacy, University of Patras, Greece)
Postgraduate: Biopharmacy and Pharmacokinetics, Clinical Pharmacokinetics, Clinical Pharmacy, Drug Regulatory Framework, Quality Control and Quality Assurance (Department of Pharmacy, University of Patras, Greece)
Postgraduate:, Course coordinator “Pharmaceutical Marketing” (Department of Pharmacy, University of Patras, Greece).
Professional Affiliation
Society of Pharmaceutical Medicine, UK
British Society of Immunology, UK
Hellenic Medical Society of Great Britain, UK
International Society of Tumour Targeting, UK
World Biomedical Hellenic Association, UK
Hellenic Associate of Pharmacists, Greece
Greek Society of Pharmaceutical Medicine, Greece
Hellenic Society of Tumour Markers, Greece
Hellenic Society of Biochemistry and Molecular Biology, Greece
Prizes-Honours-Patents:
M. P. Lemos” fellowship, 1985 & 1986,
UK Cancer Research Campaign Grant, 1987-1990,
UK Research proposal evaluator, European Commission, Research Directorate, 2000-2004, Belgium. “Bombesin analogues for the diagnosis and treatment of neoplasia”, Greek national application, patent granted 2011
“Biomarkers for the identification, monitoring and treatment of prostate cancer”, USPTO application 2010, Greek national application 2012)
Selected Publications
  1. A.A. Epenetos, A.J. Munro, S. Stewart, R. Rambling, H.E. Lambert, C.G. McKenzie, P. Soutter, A. Rahemtulla, G. Hooker, G.B. Sivolapenko, D. Snook, N. Courtenay-Luck, B. Dhokia, T. Krausz, J. Taylor-Papadimitriou, H. Durbin and W. Bodmer (1987). Antibody guided irradiation of advanced ovarian cancer with intraperitoneally administered radiolabelled mononclonal antibodies J. Clin. Oncol., 5: 1890-1899.
  2. N.S. Courtenay-Luck, A.A. Epenetos, G.B. Sivolapenko, M. Larche, J.R. Barkans and M.A. Ritter (1988). Development of anti-idiotypic antibodies against tumour antigens and autoantigens in ovarian cancer patients treated intraperitoneally with mouse monoclonal antibodies. Lancet, II: 894-897.
  3. H.P. Kalofonos, T.R. Pawlikowska, A. Hemingway, N. Courtenay-Luck, B. Dhokia, D. Snook, G.B. Sivolapenko, G.R. Hooker, C.G. McKenzie, P.J. Lavender, D.G.T. Thomas and A.A. Epenetos (1989). Antibody guided diagnosis and therapy of brain gliomas using radiolabelled monoclonal antibodies against epidermal growth factor receptor and placental alkaline phsphatase. J. Nucl. Med., 30: 1636-1645.
  4. J.S. Stewart, G.B. Sivolapenko, V.Hird, K.A. Davies, M. Wallport, M.A. Ritter and A.A. Epenetos (1990). The clearance of iodine-131 labelled murine mononclonal antibody from patients’ blood by intravenous human anti-murine immunoglobulin antibody. Cancer Res., 50: 563-567.
  5. K.A.A. Davies, V. Hird, S. Stewart, G.B. Sivolapenko, P. Jose, A.A. Epenetos and M.J. Walport (1990). A study of in vivo immune complex formation and clearance in man. J. Immunol. , 144: 4613-4620.
  6. C. Schatten, N. Pateisky, N. Vavra, P. Ehrenbock, P. Angelberger, G.B. Sivolapenko, and A.A. Epenetos (1991). Lymphposcintigraphy with 123I-labelled epidermal growth factor. Lancet, 337: 295-396.
  7. G.B. Sivolapenko, C. Moreno, W. Smith, J. Corvalan, M.A. Ritter and A.A. Epenetos (1991). Xenogeneic monoclonal antibodies in the management of cancer: control of their in vivo immunogenicity and induction of specific unresponsiveness using an antibody-drug immunoconjugate. Br. J. Cancer, 64: 281-287.
  8. G.B. Sivolapenko, V. Douli, D. Pectasides, D. Skarlos, G. Sirmalis, R. Hussein, J. Cook, N.S. Courtenay-Luck, E. Merkouri, K. Konstantinides and A.A. Epenetos (1995). Breast cancer imaging with radiolabelled peptide from complementarity-determining region of antitumour antibody. Lancet, 346: 1662-1666.
Ώρες υποδοχής Προπτυχιακών Φοιτητών
Δευτέρα 10-12 π.μ
Τρίτη 9-11 π.μ